Why the study?
Does the combination of sirolimus and cyclosporin synergistically inhibit allograft rejection in rat models?
Population
Rat models of heart and kidney allograft rejection
Comparison
Combination therapy with sirolimus and… vs Individual treatments with sirolimus or…
Design
Preclinical
Authors
Loading...
Rat allograft synergy supports dose-sparing exploration in models; leaves open translation to human transplant outcomes.
Does the combination of sirolimus and cyclosporin synergistically inhibit allograft rejection in rat models?
Sirolimus and cyclosporin act synergistically to inhibit allograft rejection because subtherapeutic doses of cyclosporin reduce Th1/Th2 activity, facilitating the inhibition of signal transduction by low doses of sirolimus.
Stepkowski et al. (1997) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: